123 related articles for article (PubMed ID: 28903321)
1. Alu-based cell-free DNA: a novel biomarker for screening of gastric cancer.
Qian C; Ju S; Qi J; Zhao J; Shen X; Jing R; Yu J; Li L; Shi Y; Zhang L; Wang Z; Cong H
Oncotarget; 2017 Aug; 8(33):54037-54045. PubMed ID: 28903321
[TBL] [Abstract][Full Text] [Related]
2. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
4. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
[TBL] [Abstract][Full Text] [Related]
5. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer.
Yu J; Zhang S; Zhao B
Mol Clin Oncol; 2016 Mar; 4(3):441-449. PubMed ID: 26998301
[TBL] [Abstract][Full Text] [Related]
6. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.
Pan YQ; Ruan YY; Peng JB; Han QY; Zhang X; Lin A; Yan WH
Hum Immunol; 2016 Apr; 77(4):317-24. PubMed ID: 26788811
[TBL] [Abstract][Full Text] [Related]
9. Mir-421 in plasma as a potential diagnostic biomarker for precancerous gastric lesions and early gastric cancer.
Chen J; Wu L; Sun Y; Yin Q; Chen X; Liang S; Meng Q; Long H; Li F; Luo C; Xiao X
PeerJ; 2019; 7():e7002. PubMed ID: 31245174
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
11. A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4).
Guo J; Chen S; Li S; Sun X; Li W; Zhou Z; Chen Y; Xu D
Oncotarget; 2018 Jan; 9(4):4814-4822. PubMed ID: 29435143
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.
Ohuchi N; Takahashi K; Matoba N; Sato T; Taira Y; Sakai N; Masuda M; Mori S
Jpn J Clin Oncol; 1989 Sep; 19(3):242-8. PubMed ID: 2810823
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination.
Huang C; Liu Z; Xiao L; Xia Y; Huang J; Luo H; Zong Z; Zhu Z
Front Oncol; 2019; 9():1159. PubMed ID: 31750248
[No Abstract] [Full Text] [Related]
16. [Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9].
Takahashi Y; Mai M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):515-8. PubMed ID: 1558402
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
[TBL] [Abstract][Full Text] [Related]
19. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
20. [The significance of pepsinogen with its subgroup and CA72-4 associate detect applied to early diagnostic and prognosis judgment on gastric cancer].
Lin HZ; Chen L; Li XC; Zhou DF; Cui JY
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1505-8. PubMed ID: 15733483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
